Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms Dopascan + [3] |
Target |
Mechanism DAT antagonists(Dopamine transporter antagonists), SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
Regulation- |
Molecular FormulaC16H20INO2 |
InChIKeySIIICDNNMDMWCI-LTFFGQHJSA-N |
CAS Registry136794-86-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Parkinson Disease | NDA/BLA | - | - | |
Parkinson Disease | NDA/BLA | - | - | |
Parkinson Disease | NDA/BLA | FI | - | - |
Parkinson Disease | NDA/BLA | - | - | |
Parkinson Disease | NDA/BLA | - | - | |
Parkinson Disease | Phase 1 | FI | - | - |
Parkinson Disease | Phase 1 | - | - | |
Parkinson Disease | Phase 1 | - | - |
Phase 2 | 142 | Placebo (Placebo Group) | vayhudyumc(wljfpfffuh) = ogefrwujrt auqefhxxzz (qrykcspqqw, vjwehgddkl - gatxnlkpom) | - | 08 Aug 2014 | ||
Levodopa (Levodopa) | vayhudyumc(wljfpfffuh) = ycsctjxyzg auqefhxxzz (qrykcspqqw, yaskvpdosd - kdojflwhme) |